Novo insulin beats Sanofi's Lantus in a comparative trial

05/5/2011 | Reuters

Novo Nordisk said degludec, an experimental long-acting insulin, proved superior to Sanofi-Aventis' best-seller Lantus in reducing hypoglycemia, particularly a nocturnal event, among patients with diabetes during a Phase IIIa trial. Novo Nordisk aims to market degludec and another formulation, degludec plus, during the first half of 2012.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC